HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Health, Beauty And Wellness News: FTC, ADM, Hain, CRN, Boston Therapeutics

This article was originally published in The Rose Sheet

Executive Summary

AuraVie 'risk free' marketer enforcement closes; ADM makes second proibiotics move; Hain Celestial announces CEO succession plan; CRN updates guidelines on SARMs, caffeine; and Sugardown supplement added to Kathy Ireland band.

You may also be interested in...



Supplements For Disease-Related Nutrition Shaping Consumer Health Landscape

Sales of dietary supplements promoted for nutritional needs of diabetics are exploding as consumers seek non-drug products to deal with symptoms of the disease, says a consumer health analyst in a recent presentation. Consumer health products positioned to prevent disease are growing at a much faster rate globally than those formulas that treat ailments.

FDA Brews Two Caffeine Dosage Warnings Six Weeks After Guidance

The agency publishes warning letters to liquidcaffeine.com, operated by Liquid Caffeine Inc., and Dual Health Body & Mind Inc. explaining that some of their highly concentrated caffeine products are adulterated and a threat to public health.

SARMs Subject To Steroids Scheduling By DEA Under Hatch, Whitehouse Bill

The Utah Republican and Rhode Island Democrat sponsor legislation to make selective androgen receptor modulators subject to the same authority the Drug Enforcement Administration has to regulate anabolic steroids. Hatch said the SARMs Control Act of 2018 would "ensure that the DEA has the authority it needs to prevent abuse and diversion of these dangerous substances.”

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS121694

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel